Table 1.

Current status of dengue vaccine candidates based on live attenuated or purified inactivated virus.

Vaccine candidate and developer	Approach and type of vaccine	Status	References
Dengvaxia® (CYD-TDV); Sanofi Pasteur	YF-17D backbone with prM and E genes of dengue virus 1-4 (Live attenuated vaccine)	Licensed	(58)
TetraVax-DV-TV003/TV005; NIAID/NIH	Full length dengue virus 1/2/3/4 lacking 30 nt in 3′UTR (Live attenuated vaccine)	Phase III	(59, 60)
DENVax/TAK003/TDV; Takeda/Inviragen	Dengue virus 2 PDK53 backbone with dengue virus 1,3 and 4 prM and E gene chimera (Live attenuated vaccine)	Phase III	(61)
TDEN; WRAIR/GSK	Dengue virus 1/2/3/4 PDK virus (Live attenuated vaccine)	Phase II	(62)
TDEN PIV; WRAIR/GSK/Fiocruz	Formalin inactivated dengue virus 1/2/3/4 (Purified inactivated vaccine)	Phase I	(63)